G Liu1, J Geng1. 1. Department of Neurology, First Affiliated Hospital of Kunming Medical University, Kunming, China.
Abstract
BACKGROUND: We investigated the association between serum levels of glial fibrillary acidic protein (GFAP) and stroke functional outcomes in a cohort of 286 patients with acute ischemic stroke (AIS). METHODS: We prospectively studied 286 patients with AIS who were admitted within 24 h after the onset of symptoms. Serum levels of GFAP and National Institutes of Health Stroke Scale (NIHSS) were measured at admission. The primary end point was stroke functional outcome among 1-year after stroke onset. We used logistic regression models to assess the relationship between GFAP levels and stroke outcomes. RESULTS: The GFAP level was obtained with a median value of 0.18 (interquartile ranges (IQRs): 0.09-0.28) ng/ml. In multivariable models adjusted for age, gender, and other risk factors, GFAP levels were associated with an increased risk of a NIHSS>6 (odds ratio (OR) = 1.55; 95% confidence interval (CI): 1.16-1.89; p = 0.012). The poor outcome distribution across the GFAP quartiles ranged between 12.7% (first quartile) and 70.4% (fourth quartile). After adjusting for other established risk factors, in multivariate models comparing the Q3 and Q 4 quartiles against the Q1 of the GFAP, the levels of GFAP were associated with poor outcome, and the adjusted risk of poor outcome increased by 211% (3.11[1.80-5.05], p < 0.001) and 522% (6.22[2.98-11.83], p < 0.001), respectively. Interestingly, GFAP improved the ability of NIHSS score to diagnose poor outcomes (area under the curve [AUC] of the combined model 0.82; 95% CI: 0.77-0.88; p = 0.02). CONCLUSION: GFAP levels are a novel and complementary biomarker to predict functional outcome 1 year after AIS.
BACKGROUND: We investigated the association between serum levels of glial fibrillary acidic protein (GFAP) and stroke functional outcomes in a cohort of 286 patients with acute ischemic stroke (AIS). METHODS: We prospectively studied 286 patients with AIS who were admitted within 24 h after the onset of symptoms. Serum levels of GFAP and National Institutes of Health Stroke Scale (NIHSS) were measured at admission. The primary end point was stroke functional outcome among 1-year after stroke onset. We used logistic regression models to assess the relationship between GFAP levels and stroke outcomes. RESULTS: The GFAP level was obtained with a median value of 0.18 (interquartile ranges (IQRs): 0.09-0.28) ng/ml. In multivariable models adjusted for age, gender, and other risk factors, GFAP levels were associated with an increased risk of a NIHSS>6 (odds ratio (OR) = 1.55; 95% confidence interval (CI): 1.16-1.89; p = 0.012). The poor outcome distribution across the GFAP quartiles ranged between 12.7% (first quartile) and 70.4% (fourth quartile). After adjusting for other established risk factors, in multivariate models comparing the Q3 and Q 4 quartiles against the Q1 of the GFAP, the levels of GFAP were associated with poor outcome, and the adjusted risk of poor outcome increased by 211% (3.11[1.80-5.05], p < 0.001) and 522% (6.22[2.98-11.83], p < 0.001), respectively. Interestingly, GFAP improved the ability of NIHSS score to diagnose poor outcomes (area under the curve [AUC] of the combined model 0.82; 95% CI: 0.77-0.88; p = 0.02). CONCLUSION:GFAP levels are a novel and complementary biomarker to predict functional outcome 1 year after AIS.
Authors: Thomas Gattringer; Christian Enzinger; Daniela Pinter; Simon Fandler-Höfler; Markus Kneihsl; Melanie Haidegger; Sebastian Eppinger; Rina Demjaha; Arabella Buchmann; Andrea Jerkovic; Reinhold Schmidt; Michael Khalil Journal: J Neurol Date: 2022-09-03 Impact factor: 6.682
Authors: Ahmed Abdelhak; Matteo Foschi; Samir Abu-Rumeileh; John K Yue; Lucio D'Anna; Andre Huss; Patrick Oeckl; Albert C Ludolph; Jens Kuhle; Axel Petzold; Geoffrey T Manley; Ari J Green; Markus Otto; Hayrettin Tumani Journal: Nat Rev Neurol Date: 2022-02-03 Impact factor: 44.711